7 results about "Development drugs" patented technology

The application discloses a sensitized ferroptosis lipid nano regulator and a preparation method and application thereof, and belongs to the technical field of new adjuvants and new dosage forms of drug preparation combined treatment. The lipid nano regulator is co-assembled by a GPX4 inhibitor and a FASN inhibitor through intermolecular forces, and is modified with an oxidation-reduction sensitive PEG modifier, a molar ratio of the GPX4 inhibitor and the FASN inhibitor is 10:1-1:10, a mass ratio of the sum of the GPX4 inhibitor and the FASN inhibitor to the PEG modifier is 10:90-90:10, and the intermolecular forces include pi-pi stacking force, hydrophobic force and hydrogen bond. The co-assembled nano preparation provides a new strategy and more choices for the development of drug delivery, and meets the urgent needs of high-efficiency and diverse ferroptosis treatment strategies in preparations in the clinic.

The invention discloses an antibody for specifically recognizing 1147th acetylation of ribosome biosynthetic factor 1 protein as well as a preparation method and application of the antibody. According to the protein sequence and the modification type of the ribosome biosynthetic factor 1, two modified antigen polypeptides A and B are designed, and through detection, the antibody obtained by immunizing animals with the two polypeptides has high specificity and affinity, can accurately recognize the acetylation modification form of the 1147th site of BMS1, and avoids recognition of an unmodified form or other modification sites. The antibody is suitable for various immunological detection methods, is high in repeatability and low in background, has mass production potential, can realize industrialization, not only can be used for evaluating the cis-platinum drug resistance condition in esophageal cancer treatment, but also can be used for various scenes such as basic research, disease mechanism analysis, biomarker development and drug target screening, and is wide in application range.

The present invention relates to a non-human mammal model of HSV latent infection, which enables detection of HSV in mucosal tissue upon exposure to a stimulus that reactivates latent HSV within the body. The non-human mammal according to the present invention can contribute to elucidating the mechanism of HSV latent infection and reactivation in humans and to developing drugs and the like for HSV.

The present application relates to the technical field of biological medicine, in particular to a functionalized targeted liposome and application thereof, comprising: lipids and a targeting ligand; wherein the targeting ligand can specifically bind to a TREM2 receptor. The liposome of the present application can specifically bind to the TREM2 receptor by means of the targeting ligand, realize precise targeting of cells containing the TREM2 receptor on the surface, ensure direct action on target cells, and further improve the precision of delivered substances. The liposome has targeting property, high stability, small side effects, and can be applied to the development of drug carriers, pharmaceutical compositions, etc., and has a wide application prospect. For example, the liposome of the present application is dynamically connected with a hydrogel molecule by a borate ester bond to prepare a hydrogel pharmaceutical composition containing the functionalized targeted liposome of the present application. The hydrogel pharmaceutical composition can release the liposome of the present application according to the change of pH and ROS in the surrounding environment in response to an inflammatory environment, and target cells containing the TREM2 receptor on the surface, i.e. microglial cells (having the TREM2 receptor on the surface), by virtue of the targeting ligand exposed on the surface, and regulate the polarization state of the cells, inhibit the polarization of the cells to the pro-inflammatory M1 type, and promote the polarization of the cells to the anti-inflammatory M2 type, thereby improving the local microenvironment of the spinal cord injury site and promoting nerve regeneration.

The application discloses an antibody capable of specifically recognizing acetylation of ribosome biogenesis factor 1 protein at the 1147th position, and a preparation method and application thereof. According to the protein sequence and modification type of ribosome biogenesis factor 1, two modified antigen polypeptides A and B are designed. It is detected that the antibody obtained by immunizing animals by using the two polypeptides has high specificity and affinity, and can accurately recognize the acetylation modification form of the 1147th position of BMS1, and avoid recognizing the unmodified form or other modification sites. The antibody is suitable for various immunological detection methods, has high repeatability, low background, has mass production potential, can be industrialized, and is not only used for evaluating the cisplatin resistance in esophageal cancer treatment, but also used for various scenes such as basic research, disease mechanism analysis, biomarker development, drug target screening, and has a wide application range.

The invention provides philippine violet herb polysaccharide (VP-P) as well as a preparation method and application thereof. The VP-P is composed of glucose, galactose, xylose and arabinose, the molar ratio of glucose residues to galactose residues to xylose residues to arabinose residues is 6: 4: 1: 1, and the chemical structure of the VP-P comprises (1-> 6)-galactose residues, (1-> 4)-galactose residues, (1-> 4)-glucose residues, (1-> 4)-xylose residues and (1-> 4)-arabinose residues. The philippine violet herb polysaccharide (VP-P) prepared by the invention has remarkable anti-inflammatory activity, particularly has a remarkable effect in the aspect of treating pneumonia, and provides a new support for medicine development.

The invention discloses application of bitter gourd-derived extracellular vesicle-like particles in preparation of medicines for resisting oxidation and delaying senescence. The bitter gourd extracellular vesicles provided by the invention have the effect of promoting cell activity after cell aging is induced by D-(+)-galactose so as to delay bEnd.3 cell aging, and can be used as an anti-aging raw material of cosmetics. An in-vivo experiment shows that the bitter gourd extracellular vesicles can improve rough hair of naturally aged rats, prolong the survival time of the rats, achieve the effects of resisting inflammation and oxidation and the like, and provide a new thought and basis for developing medicine aging-delaying health care products and cosmetics.